β³ Fetching live dividend data...
Home βΊ Calculator βΊ ADAG Dividend Calculator 2026
Adagene Inc. Β· NASDAQ
Price: $2.41 Β· Annual div: None Β· Frequency: β Β· Payout ratio: N/A Β· Ex-div: β
ADAG is not a dividend-focused stock
ADAG pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Adagene Inc. (ADAG) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
No. Adagene Inc. (ADAG) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
A DRIP reinvests dividends into new shares. ADAG has no regular dividend in our data, so there is nothing to reinvest.
Forward dividend yield from the latest data Β· open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open ADAG position with:
Real after-tax yield depends on where you live and how you hold ADAG.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 0.00% | -2.80% | $0 / yr |
| πΊπΈ US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| π¬π§ UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| π¨π¦ CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| π¦πΊ AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| π©πͺ DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| π«π· FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
ADAG pays quarterly β 4 times per year. Ex-div: β.
How ADAG compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADAG sourced from FMP /financial-growth endpoint β real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-09-23 | 2,000 | $3.00 | $6.0K | ||
| Buy | 2026-09-16 | 20,290 | $3.15 | $64.0K | ||
| Buy | 2026-08-14 | 2,000 | $3.75 | $7.5K | ||
| A-Award | 2026-08-13 | 20,000 | $3.00 | $60.0K | ||
| A-Award | 2026-08-13 | 20,000 | $3.00 | $60.0K | ||
| A-Award | 2026-08-13 | 20,000 | $3.00 | $60.0K | ||
| A-Award | 2026-08-13 | 20,000 | $3.00 | $60.0K | ||
| Buy | 2026-08-05 | 279 | $3.65 | $1.0K | ||
| Buy | 2026-08-04 | 22,966 | $3.65 | $83.7K | ||
| Other | 2026-03-18 | 400,000 | $2.03 | $812.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Compare ADAG with peers: ADAG vs ACET Β· ADAG vs CRVO Β· ADAG vs FBIO
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Insiders are net buyers β historically a positive signal for dividend sustainability. Last purchase: 2026-09-23
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADAG dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Adagene Inc. (ADAG) is currently trading at $2.41, 50% below its 52-week high. It does not currently pay a regular dividend.
Adagene Inc. (ADAG) is a healthcare stock trading at $2.41. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
Auto-generated from live market data. For educational purposes only β not financial advice.
News aggregated from public sources via Finnhub & RSS. For informational purposes only.
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
β±οΈ Takes 30 seconds Β· No signup Β· Free forever